ReviewNature reviews. Gastroenterology & hepatology2010
The pharmacoeconomics of biologic therapy for IBD.
Review in Nature reviews. Gastroenterology & hepatology, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 30 citations in OpenAlex.
- Article
- Unlocking hope: The future of ustekinumab biosimilars in Crohn's disease treatment.United European gastroenterology journal · 2025Review
- Inflammatory bowel disease, colitis, and cancer: unmasking the chronic inflammation link.International journal of colorectal disease · 2024Review
- Role of Digital Health and Artificial Intelligence in Inflammatory Bowel Disease: A Scoping Review.Genes · 2021Article
- TRIM34 attenuates colon inflammation and tumorigenesis by sustaining barrier integrity.Cellular & molecular immunology · 2021Article
- Recent advances in the management of perianal fistulizing Crohn's disease: lessons for the clinic.Expert review of gastroenterology & hepatology · 2019Review
- Anti-tumour necrosis factor discontinuation in inflammatory bowel disease patients in remission: study protocol of a prospective, multicentre, randomized clinical trial.Therapeutic advances in gastroenterology · 2019Article
- Emergency department utilisation for inflammatory bowel disease in the United States from 2006 to 2014.Alimentary pharmacology & therapeutics · 2018Article
- Expression profile of intestinal stem cell markers in colitis-associated carcinogenesis.Scientific reports · 2017Article
- Creatine maintains intestinal homeostasis and protects against colitis.Proceedings of the National Academy of Sciences of the United States of America · 2017Article
- Satisfaction and expectations of patients with inflammatory bowel disease on biologic therapy: a multicenter study.Annals of gastroenterology · 2017Article
- Sphingosine-1-phosphate phosphatase 2 promotes disruption of mucosal integrity, and contributes to ulcerative colitis in mice and humans.FASEB journal : official publication of the Federation of American Societies for Experimental Biology · 2016Article
- Ultrasound-based molecular imaging and specific gene delivery to mesenteric vasculature by endothelial adhesion molecule targeted microbubbles in a mouse model of Crohn's disease.Journal of controlled release : official journal of the Controlled Release Society · 2013Article
- The economic burden of inflammatory bowel disease: clear problem, unclear solution.Digestive diseases and sciences · 2012Article
- Use of the tumor necrosis factor-blockers for Crohn's disease.World journal of gastroenterology · 2012Review
- Statins are associated with reduced use of steroids in inflammatory bowel disease: a retrospective cohort study.Inflammatory bowel diseases · 2012Article
- Innate immune mechanisms of colitis and colitis-associated colorectal cancer.Nature reviews. Immunology · 2011Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The past decade has been marked by the introduction and expanding use of biologic therapies for the induction and maintenance of response in patients with IBD. Although widely heralded for their efficacy, these agents have also stirred controversy over the potential economic impact that they will have upon the world's health-care systems. Traditional cost analyses had shown that IBD medication costs contributed minimally towards the overall costs associated with the disease; however, these studies were all conducted before the introduction of biologic therapies. At that time, a small minority of patients accounted for a disproportionately large percentage of the overall costs, suggesting that cost-savings could be realized if interventions decreased the utilization of health-care resources and associated costs. More recent studies have been heterogeneous in their design and findings-some have suggested that cost-savings realized due to a decrease in the utilization of health-care services may offset the higher costs of biologic agents. Incorporation of data on indirect cost-savings and quality of life improvements into ongoing and future analyses is required to allow for more accurate analyses of overall costs and cost-savings.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.